The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin

R. C. Block, R. Duff, P. Lawrence, L. Kakinami, J. T. Brenna, G. C. Shearer, N. Meednu, S. Mousa, A. Friedman, William Harris, Mark Larson, S. Georas

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Lysophophatidylcholine (LPC) and lysophosphatidic acid (LPA) are potent lysolipid mediators increasingly linked with atherosclerosis and inflammation. A current model proposing that plasma LPA is produced when LPC is hydrolyzed by the enzyme autotaxin has not been rigorously investigated in human subjects. We conducted a clinical trial of eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) and aspirin ingestion in normal volunteers. Fasting blood samples were drawn at baseline and after 4-week supplementation with EPA/DHA (3.4. g/d) with and without aspirin (650. mg). Plasma LPC and LPA species and autotaxin activity were measured. EPA-LPC and DHA-LPC concentrations increased significantly with EPA/DHA supplementation whereas EPA- and DHA-LPA did not. Autotaxin activity was unaffected by any treatment, and aspirin had no effect on any endpoint. Taken together, our data demonstrate that plasma LPC, but not LPA, species can be dynamically regulated by dietary supplementation, and argue against a simple model of LPA generation via LPC hydrolysis.

Original languageEnglish (US)
Pages (from-to)87-95
Number of pages9
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume82
Issue number2-3
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Lysophospholipids
Aspirin
Eating
Plasmas
Eicosapentaenoic Acid
Docosahexaenoic Acids
Dietary Supplements
lysophosphatidic acid
Hydrolysis
Fasting
Atherosclerosis
Healthy Volunteers
Blood
Clinical Trials
Inflammation
Enzymes

Keywords

  • Autotaxin
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Lysophosphatidic acid
  • Lysophosphatidylcholine
  • Lysophospholipase D

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry

Cite this

Block, R. C., Duff, R., Lawrence, P., Kakinami, L., Brenna, J. T., Shearer, G. C., ... Georas, S. (2010). The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin. Prostaglandins Leukotrienes and Essential Fatty Acids, 82(2-3), 87-95. https://doi.org/10.1016/j.plefa.2009.12.005

The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin. / Block, R. C.; Duff, R.; Lawrence, P.; Kakinami, L.; Brenna, J. T.; Shearer, G. C.; Meednu, N.; Mousa, S.; Friedman, A.; Harris, William; Larson, Mark; Georas, S.

In: Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 82, No. 2-3, 02.2010, p. 87-95.

Research output: Contribution to journalArticle

Block, RC, Duff, R, Lawrence, P, Kakinami, L, Brenna, JT, Shearer, GC, Meednu, N, Mousa, S, Friedman, A, Harris, W, Larson, M & Georas, S 2010, 'The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin', Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 82, no. 2-3, pp. 87-95. https://doi.org/10.1016/j.plefa.2009.12.005
Block, R. C. ; Duff, R. ; Lawrence, P. ; Kakinami, L. ; Brenna, J. T. ; Shearer, G. C. ; Meednu, N. ; Mousa, S. ; Friedman, A. ; Harris, William ; Larson, Mark ; Georas, S. / The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin. In: Prostaglandins Leukotrienes and Essential Fatty Acids. 2010 ; Vol. 82, No. 2-3. pp. 87-95.
@article{c6a6bd36c79d4883b0f7178678f9f1bf,
title = "The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin",
abstract = "Lysophophatidylcholine (LPC) and lysophosphatidic acid (LPA) are potent lysolipid mediators increasingly linked with atherosclerosis and inflammation. A current model proposing that plasma LPA is produced when LPC is hydrolyzed by the enzyme autotaxin has not been rigorously investigated in human subjects. We conducted a clinical trial of eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) and aspirin ingestion in normal volunteers. Fasting blood samples were drawn at baseline and after 4-week supplementation with EPA/DHA (3.4. g/d) with and without aspirin (650. mg). Plasma LPC and LPA species and autotaxin activity were measured. EPA-LPC and DHA-LPC concentrations increased significantly with EPA/DHA supplementation whereas EPA- and DHA-LPA did not. Autotaxin activity was unaffected by any treatment, and aspirin had no effect on any endpoint. Taken together, our data demonstrate that plasma LPC, but not LPA, species can be dynamically regulated by dietary supplementation, and argue against a simple model of LPA generation via LPC hydrolysis.",
keywords = "Autotaxin, Docosahexaenoic acid, Eicosapentaenoic acid, Lysophosphatidic acid, Lysophosphatidylcholine, Lysophospholipase D",
author = "Block, {R. C.} and R. Duff and P. Lawrence and L. Kakinami and Brenna, {J. T.} and Shearer, {G. C.} and N. Meednu and S. Mousa and A. Friedman and William Harris and Mark Larson and S. Georas",
year = "2010",
month = "2",
doi = "10.1016/j.plefa.2009.12.005",
language = "English (US)",
volume = "82",
pages = "87--95",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",
number = "2-3",

}

TY - JOUR

T1 - The Effects of EPA, DHA, and Aspirin Ingestion on Plasma Lysophospholipids and Autotaxin

AU - Block, R. C.

AU - Duff, R.

AU - Lawrence, P.

AU - Kakinami, L.

AU - Brenna, J. T.

AU - Shearer, G. C.

AU - Meednu, N.

AU - Mousa, S.

AU - Friedman, A.

AU - Harris, William

AU - Larson, Mark

AU - Georas, S.

PY - 2010/2

Y1 - 2010/2

N2 - Lysophophatidylcholine (LPC) and lysophosphatidic acid (LPA) are potent lysolipid mediators increasingly linked with atherosclerosis and inflammation. A current model proposing that plasma LPA is produced when LPC is hydrolyzed by the enzyme autotaxin has not been rigorously investigated in human subjects. We conducted a clinical trial of eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) and aspirin ingestion in normal volunteers. Fasting blood samples were drawn at baseline and after 4-week supplementation with EPA/DHA (3.4. g/d) with and without aspirin (650. mg). Plasma LPC and LPA species and autotaxin activity were measured. EPA-LPC and DHA-LPC concentrations increased significantly with EPA/DHA supplementation whereas EPA- and DHA-LPA did not. Autotaxin activity was unaffected by any treatment, and aspirin had no effect on any endpoint. Taken together, our data demonstrate that plasma LPC, but not LPA, species can be dynamically regulated by dietary supplementation, and argue against a simple model of LPA generation via LPC hydrolysis.

AB - Lysophophatidylcholine (LPC) and lysophosphatidic acid (LPA) are potent lysolipid mediators increasingly linked with atherosclerosis and inflammation. A current model proposing that plasma LPA is produced when LPC is hydrolyzed by the enzyme autotaxin has not been rigorously investigated in human subjects. We conducted a clinical trial of eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) and aspirin ingestion in normal volunteers. Fasting blood samples were drawn at baseline and after 4-week supplementation with EPA/DHA (3.4. g/d) with and without aspirin (650. mg). Plasma LPC and LPA species and autotaxin activity were measured. EPA-LPC and DHA-LPC concentrations increased significantly with EPA/DHA supplementation whereas EPA- and DHA-LPA did not. Autotaxin activity was unaffected by any treatment, and aspirin had no effect on any endpoint. Taken together, our data demonstrate that plasma LPC, but not LPA, species can be dynamically regulated by dietary supplementation, and argue against a simple model of LPA generation via LPC hydrolysis.

KW - Autotaxin

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - Lysophosphatidic acid

KW - Lysophosphatidylcholine

KW - Lysophospholipase D

UR - http://www.scopus.com/inward/record.url?scp=77951634698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951634698&partnerID=8YFLogxK

U2 - 10.1016/j.plefa.2009.12.005

DO - 10.1016/j.plefa.2009.12.005

M3 - Article

C2 - 20106646

AN - SCOPUS:77951634698

VL - 82

SP - 87

EP - 95

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

IS - 2-3

ER -